Alexander Seyf, CEO, Autolomous | Onyx Live | Advanced Therapies 2026

Cell therapies cost over $100,000 per patient to manufacture – and unlike traditional drugs, every new patient requires an entirely new production run from scratch.

With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.

Autolomous is tackling this head-on with AutoloMATE – a cloud-native, no-code software platform purpose-built for cell and gene therapy manufacturing. The platform digitises batch manufacturing records, automates scheduling and quality release, and enables instantaneous tech transfer between facilities. Key milestones include:

• Awarded a £1.2 million grant by UK Research and Innovation (UKRI) to digitise Process Analytical Technologies
• Partnered with BioCentriq and the Center for Breakthrough Medicines to deploy digital manufacturing solutions at scale
• Co-leading the Digital PIONEER Program with Adva Biotechnology and GenCART Inc. – advancing decentralised, scalable cell therapy manufacturing

At Advanced Therapies 2026, Onyx sat down with CEO, Alexander Seyf, to find out more.

A special thanks to our Onyx Live sponsors:

HUMPHREYS LAW – a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/

Panacea – AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/